Total Funding
49
53
Total FundingPost-IPO Equity raised
Growth Score
-12 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
87529
Curis is a developed erivedge, a capsule manufactured for the treatment of adults with skin cancer.
James Dentzer: President and Chief Executive OfficerPast Role: Valeritas, Chief Financial Officer
Felix Geissler: VP Medical AffairsPast Role: Lumicell, Chief Medical Officer
About the Company
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previous
experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.
